- Published on
Infectious Disease - Varicella or chickenpox
ESSENTIALS DESCRIPTION
A rash with concurrently present various stages of evolution (containing combinations of macules, papules, vesicles, and pustules) is the hallmark of chickenpox, a feverish, highly contagious illness that typically affects young children and is caused by a primary infection with the varicella zoster virus (VZV).
The study of epidemiology
The prevalence
• It is found all throughout the world and manifests as outbreaks in the late winter and early spring.
• 90% of vulnerable subjects experience a primary attack, and 70–90% of the same family experiences a secondary attack.
• Because of the immunization campaign, the incidence is declining (1). The frequency
• In two US towns where varicella is recorded, the incidence decreased by 90% between 1995 and 2005 as a result of vaccination (2).
• Moreover, related deaths, complications, expenses, and hospitalizations have decreased (2).
Males and females are the dominant sexes.
• Close contact between a nonimmune individual and a patient who is spreading the virus (exposure to varicella or herpes zoster) is a risk factor.
About 90% of occurrences occur in youngsters under the age of three. • Of people aged ≥15, 90% are immune, whereas 10% are still vulnerable.
• The number of instances in adulthood is rising.
OVERALL PREVENTION
Until the patient is no longer contagious, they must be kept out of school: Until all of the vesicles have crusted, a patient is contagious 48 hours before the rash appears (at the conclusion of the incubation period).
Immunization via Passive
• Varicella zoster immunoglobulin ought to be administered subsequent to
exposure to cases of herpes zoster or chickenpox in the following groups: susceptible pregnant women; susceptible immunocompetent adults and adolescents; and susceptible immunocompromised youngsters
- newborns born to mothers who contract chickenpox five days prior to or two days following delivery - Premature newborns admitted to hospitals (birth weight <1000 g, regardless of maternal history, or ≥28 weeks gestation when mother has no history chickenpox)< />pan>
• It should be injected intramuscularly within 96 hours, ideally within 72 hours, of exposure. Newborns receive 125U, while everyone else receives 125U/10 kg body weight (up to 625U).
Vaccination: Since 1995, the US has licensed the live attenuated VZV vaccine (Varivax: 0.5 mL s.c.) (1). In the United States, children older than 12 months are typically advised to receive two doses of this vaccination (3).
• Attenuated virus vaccination at ages 4–6 years and 12–15 months. With a minimum of three months between doses, the second dose may be given prior to age four (3).
• Children between the ages of 12 months and 12 years must wait at least 3 months between doses; however, if the gap is at least 28 days, the second dose may be accepted. For kids who are at least 13 years old, the minimum
There is a 28-day gap between dosages (3).
• It is recommended that adults without a history of chickenpox who have not received the vaccination receive it. Give two doses separated by at least 28 days if you have never been vaccinated, or the second dose if you have received just one dose (3).
• The VZV vaccine can also be given in combination with the measles, mumps, rubella, and varicella vaccines.
Pathophysiology
The respiratory mucous membranes allow the virus to enter the body, where it multiplies in local lymph nodes. Primary cell associated viremia is the means by which peripheral blood mononuclear cells become infected. The virus spreads to cutaneous epithelial cells by a secondary viremia. In ganglia, it stays dormant for life (4).
ETIOLOGY • Varicella zoster virus (HHV-3, DNA virus, genus: Varicellovirus, family: Herpesviridae).
• VZV does not have a recognized animal reservoir. The only reservoir is humans.
• Person-to-person contact is the means of transmission; the virus replicates in the nasopharynx or upper respiratory tract and is transmitted through the respiratory system and vesicle fluid.
respiratory system.
History of Diagnosis
• The duration of incubation is 10–14 days, with a range of 10–21 days.
• Affected systems include the skin, respiratory, central nervous system, disseminated/viremia, and other viscera.
Children who are immunocompetent may experience prodromal symptoms 1-2 days before the rash appears. low-grade fever and malaise.
• Constitutional symptoms include anorexia, pruritus, malaise, low-grade fever, and listlessness.
Rash.
Patients with weakened immune systems
• A greater number of hemorrhagic-based lesions.
• Three times longer healing time.
• More likely to experience visceral problems (30–50% of instances; 15% of those are deadly).
Adults
• A more serious condition. • A higher chance of visceral problems.
Women Who Are Expectant
more susceptible to congenital transmission to the fetus and maternal pneumonia (4).
Varicella in perinatal
• High mortality rate (30%) • Progressive disease involving viscera, especially the lung, and death in the infant may result from the mother contracting chickenpox 5 days prior to delivery and 48 hours following.
Varicella congenital
Severe deformities (skin scarring, hypoplastic extremities, anomalies of the eyes, and CNS dysfunction) can result from a teratogenic virus infection of the fetus during the first two trimesters of pregnancy.
MEDICAL EXAMINATION
• Rash: Spreads centripetally from the face and trunk. Mucous membranes may be affected, and
the vagina. Maculopapular at first, it transforms into vesicles that contain transparent fluid. After a few hours, the fluid becomes purulent. Lesions range in size from 5 to 13 mm in diameter, round or oval, and have an erythematous base. As the healing process advances, central umbilication emerges. The development of new lesions is followed and coexisted with by crust formation. Every type of lesion is simultaneously present at different phases of development. Lesions typically develop in subsequent crops over a period of two to four days.
• Within a week or two of commencement, the crusts break off, leaving a slightly depressed patch of skin that is scar-free unless it is superinfected.
Diagnostic Examinations and Interpretation Laboratory
Although the diagnosis is primarily clinical, it should be remembered that novice doctors have little knowledge of chickenpox (1).
PCR analysis of a clinical samples to detect VZV DNA (1, 5). The most dependable technique is PCR.
It takes roughly three days to isolate VZV from material extracted from the bottom of the lesions (viral culture).
Multinucleated giant cells are visible in a Tzanck smear taken from the bottom of a vesicle.
VZV detection in smears using direct
tests such as immunofluorescence staining (DFA).
• Serology: Convalescent serum samples with a fourfold or higher rise in IgG antibody (ELISA test) or seroconversion (positive IgM antibody). There may not be a fourfold rise in vaccinated subjects (5). Imagining
• Only 10% of individuals with positive chest x-rays experience clinical respiratory symptoms; 16% of chickenpox patients have abnormalities in their chest x-rays.
• Increased reticular shadowing or a nodular pattern are signs of pneumonitis.
DISTINCTIVE DIAGNOSIS
• Infection with the herpes simplex virus that spreads among atopic dermatitis patients.
Coxsackievirus, echoviruses, scabies, papular urticaria, dermatitis herpetiformis, folliculitis, parapsoriasis, and atypical measles can all cause widespread rashes.
• Rickettsialpox (also known as "herald spot" in serology) at the mite bite site.
MEDICATION FOR TREATMENT
First Phrase
• Within 24 hours of the disease's beginning, oral acyclovir is advised for varicella.
• Immunocompetent kids ≥2 years old and weighing ≤40 kg: taken orally in four dosages per day for five days at a maximum of 80 mg/kg/day.
• Adults or children above 40 kg: 3200 mg taken orally four times a day for five days.
• Patients must drink enough water.
• For seven days, apply a topical solution to each lesion six times a day.
Line Two
• Famciclovir (adults: 500 mg orally three times daily for seven days; not established for children under the age of eighteen) and valacyclovir (children 2–18 years: 20 mg/kg; adults: 1 g orally three times daily for seven days) are more effective against VZV and have superior absorption compared to acyclovir. There is little information on valacyclovir's ability to treat chickenpox.
• Although myelosuppression is a significant and frequent side effect, ganciclovir is also effective against VZV.
ADDITIONAL MEDICATION
Overall Actions
• Unless a problem arises or the patient is at high risk for problems (such as pregnant women or individuals with impaired immune systems), appropriate medical care is typically provided as an outpatient.
• Astringent soaks, cautious bathing, and closely clipped fingernails to avoid scratching are general precautions.
Oral antipruritic medications.
• Antibiotics applied topically to treat bacterial infections.
• For fever, take paracetamol or acetaminophen.
• Acetylsalicylic acid, or aspirin, increases the risk of developing Reye's syndrome.
Continuing Care Follow-Up Suggestions
Monitoring of Patients
In high-risk groups, keep an eye on respiratory function (% hemoglobin O2 saturation).
PATIENT EDUCATION • Following immunization, a person should avoid contact with a pregnant woman for three months and refrain from taking aspirin for six weeks.
• Getting vaccinated while pregnant is not advised. • Explain to the patient how contagious the illness is.
PROGNOSIS: The majority of instances are minor.
• The virus stays dormant in the sensory ganglia, and herpes zoster is caused by reactivation (secondary infection).
• Lifelong immunity is nearly always produced by varicella.
• Immunocompromised patients, adults, pregnant women, and their unborn child may be at risk for death.
DIFFICULTIES
• In the US, the average yearly death toll from 2003 to 2005 was 16.
• A secondary bacterial infection primarily caused by group A streptococci or staphylococci. The neutropenic host may develop a systemic infection as a result.
• Varicella pneumonia primarily affects immunocompromised patients and adults (1 in 400 cases). During the second or third trimester of pregnancy, it might be fatal. Tachypnea, cough, dyspnea, and fever are the symptoms that often appear three to five days after the sickness starts. An x-ray of the chest reveals interstitial or nodular pneumonitis. Even when there are no clinical symptoms, alterations on chest x-rays may be visible.
• Cerebellar ataxia can occur up to 21 days after the rash first appears, but generally within a week. It affects 1 in 4000 people and typically occurs in those under the age of 15. Ataxia, vertigo, fever, tremor, emesis, and dysphasia are among the symptoms. Examining the cerebrospinal fluid reveals increased protein and lymphocytosis. It usually goes away in two to four weeks and is a benign consequence.
• In the first week of illness, 0.1–0.2% of patients develop encephalitis, which can be fatal in adults. It manifests as a lower degree of
seizures, fever, changed cognitive processes, headache, vomiting, and consciousness. The mortality rate is between 5 and 20%, and 15% of survivors have neurologic sequelae. It lasts for at least two weeks.
• Transverse myelitis and meningitis; • Reye's syndrome, which manifests in the latter stages of the illness and has been epidemiologically linked to aspirin intake. In addition to myocarditis, nephritis, bleeding diathesis, and (rarely) hepatitis, it manifests as vomiting, restlessness, irritability, a progressive decline in consciousness, progressive cerebral edema, hyperammonemia, bleeding diathesis, hyperglycemia, and increased transaminases.
ESSENTIALS DESCRIPTION
A rash with concurrently present various stages of evolution (containing combinations of macules, papules, vesicles, and pustules) is the hallmark of chickenpox, a feverish, highly contagious illness that typically affects young children and is caused by a primary infection with the varicella zoster virus (VZV).
The study of epidemiology
The prevalence
• It is found all throughout the world and manifests as outbreaks in the late winter and early spring.
• 90% of vulnerable subjects experience a primary attack, and 70–90% of the same family experiences a secondary attack.
• Because of the immunization campaign, the incidence is declining (1). The frequency
• In two US towns where varicella is recorded, the incidence decreased by 90% between 1995 and 2005 as a result of vaccination (2).
• Moreover, related deaths, complications, expenses, and hospitalizations have decreased (2).
Males and females are the dominant sexes.
• Close contact between a nonimmune individual and a patient who is spreading the virus (exposure to varicella or herpes zoster) is a risk factor.
About 90% of occurrences occur in youngsters under the age of three. • Of people aged ≥15, 90% are immune, whereas 10% are still vulnerable.
• The number of instances in adulthood is rising.
OVERALL PREVENTION
Until the patient is no longer contagious, they must be kept out of school: Until all of the vesicles have crusted, a patient is contagious 48 hours before the rash appears (at the conclusion of the incubation period).
Immunization via Passive
• Varicella zoster immunoglobulin ought to be administered subsequent to
exposure to cases of herpes zoster or chickenpox in the following groups: susceptible pregnant women; susceptible immunocompetent adults and adolescents; and susceptible immunocompromised youngsters
- newborns born to mothers who contract chickenpox five days prior to or two days following delivery - Premature newborns admitted to hospitals (birth weight <1000 g, regardless of maternal history, or ≥28 weeks gestation when mother has no history chickenpox)< />pan>
• It should be injected intramuscularly within 96 hours, ideally within 72 hours, of exposure. Newborns receive 125U, while everyone else receives 125U/10 kg body weight (up to 625U).
Vaccination: Since 1995, the US has licensed the live attenuated VZV vaccine (Varivax: 0.5 mL s.c.) (1). In the United States, children older than 12 months are typically advised to receive two doses of this vaccination (3).
• Attenuated virus vaccination at ages 4–6 years and 12–15 months. With a minimum of three months between doses, the second dose may be given prior to age four (3).
• Children between the ages of 12 months and 12 years must wait at least 3 months between doses; however, if the gap is at least 28 days, the second dose may be accepted. For kids who are at least 13 years old, the minimum
There is a 28-day gap between dosages (3).
• It is recommended that adults without a history of chickenpox who have not received the vaccination receive it. Give two doses separated by at least 28 days if you have never been vaccinated, or the second dose if you have received just one dose (3).
• The VZV vaccine can also be given in combination with the measles, mumps, rubella, and varicella vaccines.
Pathophysiology
The respiratory mucous membranes allow the virus to enter the body, where it multiplies in local lymph nodes. Primary cell associated viremia is the means by which peripheral blood mononuclear cells become infected. The virus spreads to cutaneous epithelial cells by a secondary viremia. In ganglia, it stays dormant for life (4).
ETIOLOGY • Varicella zoster virus (HHV-3, DNA virus, genus: Varicellovirus, family: Herpesviridae).
• VZV does not have a recognized animal reservoir. The only reservoir is humans.
• Person-to-person contact is the means of transmission; the virus replicates in the nasopharynx or upper respiratory tract and is transmitted through the respiratory system and vesicle fluid.
respiratory system.
History of Diagnosis
• The duration of incubation is 10–14 days, with a range of 10–21 days.
• Affected systems include the skin, respiratory, central nervous system, disseminated/viremia, and other viscera.
Children who are immunocompetent may experience prodromal symptoms 1-2 days before the rash appears. low-grade fever and malaise.
• Constitutional symptoms include anorexia, pruritus, malaise, low-grade fever, and listlessness.
Rash.
Patients with weakened immune systems
• A greater number of hemorrhagic-based lesions.
• Three times longer healing time.
• More likely to experience visceral problems (30–50% of instances; 15% of those are deadly).
Adults
• A more serious condition. • A higher chance of visceral problems.
Women Who Are Expectant
more susceptible to congenital transmission to the fetus and maternal pneumonia (4).
Varicella in perinatal
• High mortality rate (30%) • Progressive disease involving viscera, especially the lung, and death in the infant may result from the mother contracting chickenpox 5 days prior to delivery and 48 hours following.
Varicella congenital
Severe deformities (skin scarring, hypoplastic extremities, anomalies of the eyes, and CNS dysfunction) can result from a teratogenic virus infection of the fetus during the first two trimesters of pregnancy.
MEDICAL EXAMINATION
• Rash: Spreads centripetally from the face and trunk. Mucous membranes may be affected, and
the vagina. Maculopapular at first, it transforms into vesicles that contain transparent fluid. After a few hours, the fluid becomes purulent. Lesions range in size from 5 to 13 mm in diameter, round or oval, and have an erythematous base. As the healing process advances, central umbilication emerges. The development of new lesions is followed and coexisted with by crust formation. Every type of lesion is simultaneously present at different phases of development. Lesions typically develop in subsequent crops over a period of two to four days.
• Within a week or two of commencement, the crusts break off, leaving a slightly depressed patch of skin that is scar-free unless it is superinfected.
Diagnostic Examinations and Interpretation Laboratory
Although the diagnosis is primarily clinical, it should be remembered that novice doctors have little knowledge of chickenpox (1).
PCR analysis of a clinical samples to detect VZV DNA (1, 5). The most dependable technique is PCR.
It takes roughly three days to isolate VZV from material extracted from the bottom of the lesions (viral culture).
Multinucleated giant cells are visible in a Tzanck smear taken from the bottom of a vesicle.
VZV detection in smears using direct
tests such as immunofluorescence staining (DFA).
• Serology: Convalescent serum samples with a fourfold or higher rise in IgG antibody (ELISA test) or seroconversion (positive IgM antibody). There may not be a fourfold rise in vaccinated subjects (5). Imagining
• Only 10% of individuals with positive chest x-rays experience clinical respiratory symptoms; 16% of chickenpox patients have abnormalities in their chest x-rays.
• Increased reticular shadowing or a nodular pattern are signs of pneumonitis.
DISTINCTIVE DIAGNOSIS
• Infection with the herpes simplex virus that spreads among atopic dermatitis patients.
Coxsackievirus, echoviruses, scabies, papular urticaria, dermatitis herpetiformis, folliculitis, parapsoriasis, and atypical measles can all cause widespread rashes.
• Rickettsialpox (also known as "herald spot" in serology) at the mite bite site.
MEDICATION FOR TREATMENT
First Phrase
• Within 24 hours of the disease's beginning, oral acyclovir is advised for varicella.
• Immunocompetent kids ≥2 years old and weighing ≤40 kg: taken orally in four dosages per day for five days at a maximum of 80 mg/kg/day.
• Adults or children above 40 kg: 3200 mg taken orally four times a day for five days.
• Patients must drink enough water.
• For seven days, apply a topical solution to each lesion six times a day.
Line Two
• Famciclovir (adults: 500 mg orally three times daily for seven days; not established for children under the age of eighteen) and valacyclovir (children 2–18 years: 20 mg/kg; adults: 1 g orally three times daily for seven days) are more effective against VZV and have superior absorption compared to acyclovir. There is little information on valacyclovir's ability to treat chickenpox.
• Although myelosuppression is a significant and frequent side effect, ganciclovir is also effective against VZV.
ADDITIONAL MEDICATION
Overall Actions
• Unless a problem arises or the patient is at high risk for problems (such as pregnant women or individuals with impaired immune systems), appropriate medical care is typically provided as an outpatient.
• Astringent soaks, cautious bathing, and closely clipped fingernails to avoid scratching are general precautions.
Oral antipruritic medications.
• Antibiotics applied topically to treat bacterial infections.
• For fever, take paracetamol or acetaminophen.
• Acetylsalicylic acid, or aspirin, increases the risk of developing Reye's syndrome.
Continuing Care Follow-Up Suggestions
Monitoring of Patients
In high-risk groups, keep an eye on respiratory function (% hemoglobin O2 saturation).
PATIENT EDUCATION • Following immunization, a person should avoid contact with a pregnant woman for three months and refrain from taking aspirin for six weeks.
• Getting vaccinated while pregnant is not advised. • Explain to the patient how contagious the illness is.
PROGNOSIS: The majority of instances are minor.
• The virus stays dormant in the sensory ganglia, and herpes zoster is caused by reactivation (secondary infection).
• Lifelong immunity is nearly always produced by varicella.
• Immunocompromised patients, adults, pregnant women, and their unborn child may be at risk for death.
DIFFICULTIES
• In the US, the average yearly death toll from 2003 to 2005 was 16.
• A secondary bacterial infection primarily caused by group A streptococci or staphylococci. The neutropenic host may develop a systemic infection as a result.
• Varicella pneumonia primarily affects immunocompromised patients and adults (1 in 400 cases). During the second or third trimester of pregnancy, it might be fatal. Tachypnea, cough, dyspnea, and fever are the symptoms that often appear three to five days after the sickness starts. An x-ray of the chest reveals interstitial or nodular pneumonitis. Even when there are no clinical symptoms, alterations on chest x-rays may be visible.
• Cerebellar ataxia can occur up to 21 days after the rash first appears, but generally within a week. It affects 1 in 4000 people and typically occurs in those under the age of 15. Ataxia, vertigo, fever, tremor, emesis, and dysphasia are among the symptoms. Examining the cerebrospinal fluid reveals increased protein and lymphocytosis. It usually goes away in two to four weeks and is a benign consequence.
• In the first week of illness, 0.1–0.2% of patients develop encephalitis, which can be fatal in adults. It manifests as a lower degree of
seizures, fever, changed cognitive processes, headache, vomiting, and consciousness. The mortality rate is between 5 and 20%, and 15% of survivors have neurologic sequelae. It lasts for at least two weeks.
• Transverse myelitis and meningitis; • Reye's syndrome, which manifests in the latter stages of the illness and has been epidemiologically linked to aspirin intake. In addition to myocarditis, nephritis, bleeding diathesis, and (rarely) hepatitis, it manifests as vomiting, restlessness, irritability, a progressive decline in consciousness, progressive cerebral edema, hyperammonemia, bleeding diathesis, hyperglycemia, and increased transaminases.
0 Comments
